Literature DB >> 33426157

Quantitative REM Sleep without Atonia in Parkinson's Disease and Essential Tremor.

Thomas R Gossard1, Stuart J McCarter1,2, Evan Gorres1, John C Feemster1, Paul C Timm1, Luke N Teigen1, Christy L Ralston1,3, Sarah M Westerland1, Jimmy P Conway1,4, Jack T Jagielski1,4, Carl D Olson1,5, Liam J Edgar1,5, Emma L Veum1,4, Rodolfo Savica2,6, Brad F Boeve2, Michael H Silber1,2, Erik K St Louis1,2.   

Abstract

BACKGROUND: Rapid eye movement (REM) sleep behavior disorder (RBD) occurs occasionally in essential tremor (ET), but polysomnographic REM sleep without atonia (RSWA) analyses have been sparse.
OBJECTIVE: To characterize the amount and distribution of polysomnographic RSWA, the electrophysiologic substrate of RBD, in patients with Parkinson's disease (PD) and ET.
METHODS: We analyzed quantitative RSWA in 73 patients: PD (23), ET (23), and age-sex-matched controls (27). None had dream-enactment behavior history or received antidepressants. Phasic, tonic, "any," and phasic-burst duration RSWA measures were calculated in the submentalis (SM) and anterior tibialis (AT) muscles. The automated REM atonia index (RAI) was also determined. Statistical analysis was performed by Kruskal-Wallis rank-sum and Mann-Whitney tests.
RESULTS: SM phasic RSWA was significantly greater for PD than ET patients and controls (12.5% ± 12.8% vs. 4.9% ± 6.7%, 3.9% ± 2.6%), as was SM "any" (13.54% ± 14.30% vs. 5.2% ± 7.6%, 4.2% ± 2.6%). RAI was significantly lower in PD than in ET and controls (0.78 ± 0.23 vs. 0.92 ± 0.09 vs. 0.90 ± 0.17, P ≤ 0.005), but no different between ET and controls. AT phasic and "any" RSWA was similar between the 3 groups. ET and control RSWA was similar in all measures. Two ET patients (8.7%) had SM RSWA similar to PD patients.
CONCLUSIONS: Elevated SM RSWA distinguished PD from ET in patients without dream-enactment symptoms and occurs frequently in PD patients, and in isolated tremor suggests underlying synucleinopathy. Prospective studies will further validate these findings.
© 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  REM sleep without atonia, RSWA, REM sleep, behavior disorder, RBD, essential tremor, diagnosis, polysomnography, PSG.

Year:  2020        PMID: 33426157      PMCID: PMC7780943          DOI: 10.1002/mdc3.13112

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  35 in total

1.  Purkinje cell axonal anatomy: quantifying morphometric changes in essential tremor versus control brains.

Authors:  Rachel Babij; Michelle Lee; Etty Cortés; Jean-Paul G Vonsattel; Phyllis L Faust; Elan D Louis
Journal:  Brain       Date:  2013-09-12       Impact factor: 13.501

2.  Prevalence of rapid eye movement sleep behavior disorder (RBD) in Parkinson's disease: a meta and meta-regression analysis.

Authors:  Xiaona Zhang; Xiaoxuan Sun; Junhong Wang; Liou Tang; Anmu Xie
Journal:  Neurol Sci       Date:  2016-10-21       Impact factor: 3.307

3.  Validation of the Mayo Sleep Questionnaire to screen for REM sleep behavior disorder in an aging and dementia cohort.

Authors:  Bradley F Boeve; Jennifer R Molano; Tanis J Ferman; Glenn E Smith; Siong-Chi Lin; Kevin Bieniek; Wael Haidar; Maja Tippmann-Peikert; David S Knopman; Neill R Graff-Radford; John A Lucas; Ronald C Petersen; Michael H Silber
Journal:  Sleep Med       Date:  2011-02-23       Impact factor: 3.492

4.  Improved computation of the atonia index in normal controls and patients with REM sleep behavior disorder.

Authors:  Raffaele Ferri; Francesco Rundo; Mauro Manconi; Giuseppe Plazzi; Oliviero Bruni; Alessandro Oldani; Luigi Ferini-Strambi; Marco Zucconi
Journal:  Sleep Med       Date:  2010-10       Impact factor: 3.492

5.  Essential tremor associated with focal nonnigral Lewy bodies: a clinicopathologic study.

Authors:  Elan D Louis; Lawrence S Honig; Jean Paul G Vonsattel; Demetrius M Maraganore; Sarah Borden; Carol B Moskowitz
Journal:  Arch Neurol       Date:  2005-06

6.  Sleep Disturbances in Essential Tremor and Parkinson Disease: A Polysomnographic Study.

Authors:  Banu Ozen Barut; Nida Tascilar; Armagan Varo
Journal:  J Clin Sleep Med       Date:  2015-06-15       Impact factor: 4.062

7.  Polysomnographic features of REM sleep behavior disorder: development of a scoring method.

Authors:  O Lapierre; J Montplaisir
Journal:  Neurology       Date:  1992-07       Impact factor: 9.910

8.  Risk of incident Parkinson's disease and parkinsonism in essential tremor: a population based study.

Authors:  J Benito-León; E D Louis; F Bermejo-Pareja
Journal:  J Neurol Neurosurg Psychiatry       Date:  2009-04       Impact factor: 10.154

9.  Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series.

Authors:  Carlos H Schenck; Bradley F Boeve; Mark W Mahowald
Journal:  Sleep Med       Date:  2013-01-22       Impact factor: 3.492

10.  Risk and predictors of dementia and parkinsonism in idiopathic REM sleep behaviour disorder: a multicentre study.

Authors:  Ronald B Postuma; Alex Iranzo; Michele Hu; Birgit Högl; Bradley F Boeve; Raffaele Manni; Wolfgang H Oertel; Isabelle Arnulf; Luigi Ferini-Strambi; Monica Puligheddu; Elena Antelmi; Valerie Cochen De Cock; Dario Arnaldi; Brit Mollenhauer; Aleksandar Videnovic; Karel Sonka; Ki-Young Jung; Dieter Kunz; Yves Dauvilliers; Federica Provini; Simon J Lewis; Jitka Buskova; Milena Pavlova; Anna Heidbreder; Jacques Y Montplaisir; Joan Santamaria; Thomas R Barber; Ambra Stefani; Erik K St Louis; Michele Terzaghi; Annette Janzen; Smandra Leu-Semenescu; Guiseppe Plazzi; Flavio Nobili; Friederike Sixel-Doering; Petr Dusek; Frederik Bes; Pietro Cortelli; Kaylena Ehgoetz Martens; Jean-Francois Gagnon; Carles Gaig; Marco Zucconi; Claudia Trenkwalder; Ziv Gan-Or; Christine Lo; Michal Rolinski; Philip Mahlknecht; Evi Holzknecht; Angel R Boeve; Luke N Teigen; Gianpaolo Toscano; Geert Mayer; Silvia Morbelli; Benjamin Dawson; Amelie Pelletier
Journal:  Brain       Date:  2019-03-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.